Skip to main content

Table 3 Associations between SNP and breast cancer-specific mortality by anthracycline-based chemotherapy for interactions showing p < 0.1 (LRT)* in the MARIE study and results of replication in BCAC studies

From: A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

     

With anthracycline-based chemotherapy

No chemotherapy

 

SNP

Alleles

MAF

Gene

Studya

HR

95 % CI

HR

95 % CI

p for interaction*

rs733590

A > G

0.37

CDKN1A

MARIE

0.78

0.52

1.15

1.35

0.75

2.42

0.0781

  

0.35

 

BCAC

1.30

0.87

1.96

1.11

0.94

1.31

0.4857

rs3135989

A > C

0.06

LIG3

MARIE

1.67

0.87

3.20

0.84

0.26

2.72

0.0985

  

0.07

 

BCAC

1.07

0.48

2.40

0.95

0.70

1.30

0.8537

rs140697

G > A

0.10

MBD4

MARIE

0.39

0.15

0.99

0.89

0.39

2.07

0.0868

  

0.09

 

BCAC

0.93

0.42

2.07

0.84

0.62

1.15

0.9496

rs2005618

A > G

0.10

MBD4

MARIE

0.39

0.15

0.99

0.89

0.39

2.07

0.0868

  

0.09

 

BCAC

0.93

0.42

2.07

0.84

0.62

1.15

0.9563

rs1052133

C > G

0.22

OGG1

MARIE

1.25

0.85

1.83

0.63

0.29

1.37

0.0687

  

0.22

 

BCAC

0.94

0.55

1.61

0.93

0.76

1.14

0.9496

rs2269112

G > A

0.16

OGG1

MARIE

1.43

0.93

2.20

0.71

0.38

1.32

0.0976

  

0.15

 

BCAC

1.14

0.58

2.22

1.03

0.82

1.30

0.8395

rs878156

A > G

0.07

PARP2

MARIE

0.82

0.41

1.66

2.78

1.15

6.73

0.0549

  

0.07

 

BCAC

0.55

0.18

1.64

1.32

1.00

1.75

0.0361

rs3136717

A > G

0.10

POLB

MARIE

1.42

0.80

2.53

0.19

0.05

0.78

0.0218

  

0.12

 

BCAC

0.45

0.20

1.02

0.94

0.74

1.20

0.0883

rs3136781

A > C

0.10

POLB

MARIE

1.45

0.81

2.58

0.19

0.05

0.78

0.0173

  

0.11

 

BCAC

0.45

0.20

1.02

0.94

0.74

1.20

0.0909

rs3136790

A > C

0.10

POLB

MARIE

1.45

0.81

2.58

0.19

0.05

0.78

0.0191

  

0.12

 

BCAC

0.45

0.20

1.02

0.94

0.74

1.20

0.0883

rs2233921

C > A

0.45

SMUG1

MARIE

1.31

0.92

1.88

0.71

0.38

1.32

0.0156

  

0.49

 

BCAC

0.71

0.47

1.08

0.90

0.77

1.06

0.5463

rs3213255

A > G

0.43

XRCC1

MARIE

0.77

0.53

1.12

1.48

0.82

2.69

0.0712

  

0.42

 

BCAC

1.33

0.86

2.04

0.90

0.76

1.06

0.1734

rs3213356

A > G

0.44

XRCC1

MARIE

0.73

0.50

1.07

1.74

0.95

3.18

0.0267

  

0.44

 

BCAC

1.20

0.78

1.84

0.89

0.75

1.04

0.2947

  1. MAF minor allele frequency, aMARIE: With anthracycline-based chemotherapy: 477 (72 events); no chemotherapy: 696 (38 events); BCAC: With anthracycline-based chemotherapy: 766 (50 events); no chemotherapy: 4,354 (315 events). *P-value for likelihood ratio test (LRT) comparing models with and without the interaction term between SNP and anthracycline treatment